Vanguard Capital Management’s Grace Therapeutics GRCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$861K Sell
400,350
-11,364
-3% -$25.2K ﹤0.01% 3599
2026
Q2
$935K Buy
411,714
+10,058
+3% +$27.8K ﹤0.01% 3606
2026
Q1
$1.86M Buy
+401,656
New +$1.58M ﹤0.01% 3393

Other funds holding GRCE

Vanguard Capital Management's GRCE Position: Q3 2026 in Review

Vanguard Capital Management reduced its Grace Therapeutics (GRCE) stake by 2.8% in Q3 2026, selling an estimated $25.2K and leaving 400,350 shares worth $861K. The position accounts for ﹤0.01% of the portfolio, ranked #3599.

Vanguard Capital Management first reported a position in GRCE in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.86M in Q1 2026. 38 funds tracked by Wall St. Rank hold GRCE as of Q3 2026.

  • Vanguard Capital Management held 400,350 shares of Grace Therapeutics worth $861K as of Q3 2026.
  • Vanguard Capital Management sold 11,364 Grace Therapeutics shares in Q3 2026, an estimated $25.2K.
  • Grace Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3599 holding.
  • Vanguard Capital Management first reported a position in Grace Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Grace Therapeutics position peaked at $1.86M in Q1 2026.
  • 38 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.